Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers: Association with DNA replication error and shorter survival

Oncology

Volumn 57, Issue 2, 1999, Pages 149-156

  Liang, Jin Tung ^a   Chang, King Jen ^a   Chen, Jeng Chang ^a   Lee, Chun Chung ^a   Cheng, Yung Ming ^a   Hsu, Hey Chi ^a   Wu, Ming Shiang ^a   Wang, Shih Ming ^a   Lin, Jaw Town ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CDKN2A; Colorectal cancers; Mehtylation specific PCR; Methylation; MTS1; p16; p16INK4a

Indexed keywords

MICROSATELLITE DNA; PRIMER DNA; PROTEIN P16;

ARTICLE; CANCER STAGING; CHROMOSOME 18Q; CODON; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA METHYLATION; DNA REPLICATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME;

AGED; COLORECTAL NEOPLASMS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENES, P16; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; METHYLATION; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032820505     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012023     Document Type: Article

References (43)

1. Liggett WH, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-1206.
2. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshaman K, Tavtigian SV, Stochert E, Day RS III, Johnson BE, Skolnich MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
3. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
4. Sherr CJ: Mammalian G1 cyclins. Cell 1993; 73:1059-1065.
5. Nobori T, Miura K, Wu DJ, Lois A, Takahashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-756.
6. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumors. Nature 1994;370:183-184.
7. Cairns P, Tokino K, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Issacs W, Koch W, Schwab D, Sidrasky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995;11:210-212.
8. Hussusian CJ, Struewing JP, Goldstein AM, Huggins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA; Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
9. Carins P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-417.
10. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/ cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
11. Okamoto A, Demetrick DJ, Spillane EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Haris CC: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-11049.
12. Caldas C, Hahn SA, da Costa LT, Reston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS-1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
13. Wu MS, Lin YW, Sheu JC, Wang HP, Wang JT, Shung CT, Lee WJ, Wang TH, Lin JT: Intragenic homozygous deletions of MTS1 gene in gastric cancer in Taiwan, Jpn J Cancer Res 1996;87:1052-1055.
14. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Tereda M: Mutation frequency of the p16/ CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995;55:3421-3423.
15. Counts JL, Coodman JI: Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 1995;83:13-15.
16. Bird AP: The essentials of DNA methylation. Cell 1992;70:5-8.
17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;7:686-692.
18. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Johnes PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-4535.
19. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidranksy D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
20. Herman JG, Jen J, Merlo A: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1. Cancer Res 1996;56:722-727.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821-9826.
22. Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC: Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection. Hepatogastroenterology, in press.
23. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB: Rapid detection of ras oncogenes in human tumors: Application to colon, esophageal, and gastric cancer. Oncogene 1989;4:923-928.
24. Hsu HC, Tseng HW, Lai PL, Lee PH, Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res 1993;53: 4691-4694.
25. Issa JPJ, Ottariano YL, Celano P, Hamilton SR, Davidson NE, Bayling SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-540.
26. Tremblay KD, Saam JR, Ingram RS, Tilghman SM, Bartolomei MS: A paternal-specific methylation imprint marks the alleles of the mouse H19 gene. Nat Genet 1995;9:407-413.
27. Razin A, Cedar H: DNA methylation and gene expression. Microbiol Rev 1991;55:451-458.
28. Stoger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H, Barlow DP: Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993;73:61-71.
29. Singer-Sam J, Grant M, LeBon JM, Okuyama K, Chapman V, Monk M, Riggs AD: Use of Hpa II-polymerase chain reaction assay to study DNA methylation of the PgK-1 CpG island of mouse embryo at the time of X-chromosome inactivation. Mol Cell Biol 1990;10: 4987-4989.
30. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
31. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B, de la Chapelle A: Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-1648.
32. Ionov Y, Reinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561.
33. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
34. Kim H, Jen J, Vogelstein B, Hamilton SR: Clinical and pathological charactristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-156.
35. Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, Baylin SB, Issa JPJ: Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997;57:3370-3374.
36. Lengaur C, Kinzler KW, Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997; 94:2545-2550.
37. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-811.
38. Hermann JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-P, Markowitz S, Willson JKV, Hamilton SR, Kinzler KW, Kane MF, Kotodner RD, Vogelstein B, Kunkel TA, Baylin SB: Incidence of functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-6875.
39. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8598-9702.
40. Cunningham JM, Christensen ER, Tester DJ, Kim C-Y, Roche PC, Burgart LJ, Thibodeau SN: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
41. Hansen RS, Gartler SM; Scott SR, Chen SH, Laird CD: Methylation analysis of CGG sites in the CpG island of the human FMR 1 gene. Hum Mol Genet 1992;1:571-578.
42. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S: A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome. J Natl Cancer Inst 1997;89:1758-1762.
43. Mortel CG, Fleming TR, Macdonald JS, Haller DG, Lacrie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Intergroup study of fluorouracil plus levamisole adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13:2936-2943.